New Retina Radio by Eyetube
New Retina Radio is a podcast that features stories about retina that are not told elsewhere. It is produced by Retina Today and covers topics related to retina health and treatments.
Episodes
The Fellow Eye: Episode 5
Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Omesh P. Gupta, MD, retina specialist at Wills Eye Hospital, and Shane Griffin, MD, MCR, vitreoretinal surgery fellow at the University of California San Diego Shiley Eye Institute, to discuss scleral-fixating secondary IOLs. They share pearls for implantation success, advanced techniques, and tricks for handling complicated cases.
Retinal Perfusion, Sensitivity, and Function in DR
Does retinal capillary non-perfusion reliably predict functional vision loss in DR? And does the answer change how retina specialists treat it? In this episode of New Retina Radio Journal Club with VBS, Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD, discuss a prospective longitudinal cohort study examining the association between retinal sensitivity and perfusion over 2 years
Spotlight on UNITY® VCS: Experience Extraordinary
In this episode of RetinaLIVE, Kourous Rezaei, MD is joined by Lejla Vajzovic, MD, FASRS and Aleksandra Rachitskaya, MD, FASRS to discuss their experiences with UNITY® VCS in vitreoretinal surgery. The conversation covers instrument design, workflow, training and the integration of new technology in clinical practice, offering perspectives on collaboration and adapting to evolving surgical tools.
ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research
TKIs are all the rage. But what do the data tell us about their ability to effectively treat wet AMD? Akshay Thomas, MD, outlines findings from DAVIO 2, the phase 2 study assessing the safety and efficacy of EYP-1901 (EyePoint Pharmaceuticals) for the treatment of wet AMD.
And Aaron Lee, MD, MSCI, and Cecelia Lee, MD, MS, recap their Cogan Award Lecture from this year’s ARVO annual meeting. Hea
Spotlight on UNITY® VCS Dynamic Stiffener 27+
In this episode of RetinaLIVE, Christina Weng, MD, MBA, FASRS is joined by Mrinali Gupta, MD, FASRS and Omesh Gupta, MD, MBA for a conversation focused on the evolution of 27-gauge instrumentation in vitreoretinal surgery with the UNITY® VCS platform. The panel discusses their experiences adapting to new tools and techniques. Listeners will hear perspectives on integrating new technology and the o
Spotlight on UNITY® VCS: UNITY for All
Centered on the UNITY® VCS platform, this RetinaLIVE episode features Sarwar Zahid, MD, FASRS moderating a discussion with John Kitchens, MD and Matthew Cunningham, MD, FASRS. The panel shares firsthand experiences with UNITY® VCS. Listeners will discover practical insights on how the technology support both seasoned surgeons and fellows.
For Important Product Information, visit http://unityvcs.c
ARVO '26: DME Delphi Study and RHONE-X
Gaining global consensus on DME needs will dictate the terms of future drug development. Can the findings from the DME AWARE Delphi study help? Baruch Kuppermann, MD, PhD, joins the show to review the findings from a 25-doctor panel of global experts. What did they conclude regarding the unmet needs in DME?
New Retina Radio Journal Club w/ VBS: Observation vs. Vitrectomy for Floaters
When do symptomatic vitreous floaters warrant surgery, and when is observation sufficient? In this episode of New Retina Radio Journal Club with VBS, host Kyle Kovacs, MD, joins Matthew Starr, MD, and Neda Valikodath, MD, to review a major study on vision-degrading myodesopsias from vitreous floaters. They then debate the risks and value of limited refractive vitrectomy for select patients in real
The Fellow Eye: Episode 4
Co-hosts David Fell, MD, and Justin C. Muste, MD, sit down with Allen C. Ho, MD, director of Retina Research at Wills Eye Hospital, and Curtis Heisel, MD, MBA, a vitreoretinal surgery fellow at the University of California San Diego, to discuss the gene therapy landscape in retina. They share their journeys in the space, the therapies under investigation, and how fellows can get involved.
Extending Treatment Efficacy in Wet AMD
Podcast moderator Lejla Vajzovic, MD, sits down with Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi, to explore how new therapies hold promise for extending treatment efficacy in patients with wet AMD. They touch on various drug delivery platforms, gene therapy, tyrosine kinase inhibitors, and the challenges of drug development and approval.
The Retina Roundup from Medical to Surgical
Katharine Talcott, MD, and Jorge Fortun, MD, share their approaches to utilizing OCT and other retinal imaging in the clinic and the OR, detailing how OCT plays a role in the workflow of specific patient cases. They emphasize how ZEISS unites diagnostics, data management, and surgery through connectivity. They share real-world case examples for how imaging impacts the day-to-day management of pati
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Are patients with DR at higher risk for TDR, DME, vitreous hemorrhage, or blindness based on race or ethnicity ? Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, about a large retrospective cohort study examining more than 627,000 US patients with DR. The panel examines why Black and Hispanic patients faced significantly higher rates of adverse outcomes at
GLP-1 Use and AMD Risk
Could GLP-1s originally designed for diabetes and weight loss influence the risk of developing wet AMD? In this episode of New Retina Radio Journal Club with VBS, host Barton Blackorby, MD, is joined by Katharine Talcott, MD, and Hong-Uyen Hua, MD, to discuss a large national cohort study examining the relationship between GLP-1s and AMD. They explore potential biologic mechanisms, how big-data an
Spotlight on UNITY® VCS: Intelligent Fluidics
In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD welcomes Steve Charles, MD, FACS, FICS, FASRS and Maria Berrocal, MD for an in-depth conversation on the evolution of vitreoretinal surgery. The panel discusses the historical context of surgical technology, practical considerations for fluidics and intraoperative control, and the importance of adapting techniques for complex
The Fellow Eye: Episode 3
Co-hosts David Fell, MD, and Justin C. Muste, MD, are joined by Danny Mammo, MD, and Sean Berkowitz, MD, MBA, to talk all things uveitis, including challenging (and rewarding!) cases. They discuss signs of uveitis masqueraders, when to consider a diagnostic vitrectomy, how to manage patients at risk of being lost to follow-up, and ways to manage endophthalmitis.
Mentoring in Retina: Addressing Economic Diversity
Katherine E. Talcott, MD, sits down with retina mentors Yoshihiro Yonekawa, MD, and Adrienne W. Scott, MD, to discuss various strategies mentors and programs can implement to better support trainees who hale from diverse economic backgrounds.
New Retina Radio Journal Club w/ VBS: Outcomes for PDR Patients LTFU for at Least 1 Year
How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joined by Matt Starr, MD, and Nita Valikodath, MD, MS, to explore a recent paper that leveraged the power the IRIS Registry to assess real-world outcomes for this important subset of patients.
The Fellow Eye: Episode 2
Podcast co-hosts David Fell, MD, and Justin Muste, MD, are joined by Joshua H. Uhr, MD, and Arnulfo Garza-Reyes, MD, to share their experiences with scleral buckling. They discuss the utility of buckling for various cases, encircling bands versus elements, and tips for surgical success.
Practical Insights on Adopting FDA-Approved Treatments Into Practice
Join Dr. Nemo Patel, Dr. Matthew Donovan, and Dr. Danny Mammo as they share real-world insights on how the next generation of retina specialists are optimizing their patient care by adopting FDA-approved therapies for appropriate patients. Together, they explore how to navigate patient selection, safety monitoring, and workflow integration—while maintaining efficiency and patient confidence. The c
What I Wish I Knew: Insights From the Next Generation of Retina Specialists
Dr. Nemo Patel is joined by Drs. Sam Minaker and Has Al-khersan, who share lessons learned early in their careers about connecting with patients, setting expectations, and integrating therapy for geographic atrophy (GA) secondary to AMD into their respective practices. Together they address how to discuss complex diseases with patients, involve family members in treatment discussions, and build ra
The Race to Slow GA: A Retina Specialist in the Driver’s Seat of GA Treatment
Are you ready to accelerate your understanding of retina care?Join Dr. Nemo Patel as he speaks with Dr. Patrick Staropoli, a fellow retina specialist and professional race car driver, in an engaging discussion about Geographic Atrophy (GA) secondary to AMD.In this episode, Dr. Staropoli shares how the principles of racing—split-second decision-making, teamwork, and maintaining focus under pressure
New Retina Radio Journal Club w/ VBS: Diagnosis Delays in Stargardt Disease
What types of delays do Stargardt disease patients experience when it comes to diagnosis? And what are the implications for such delays? Alexis Warren, MD, is joined by Jesse Sengillo, MD, and Sruthi Arepalli, MD, to discuss findings from a recent paper quantifying delays in diagnosis and suggesting means by which such delays could be mitigated.
The Fellow Eye: Episode 1
Podcast co-hosts David Fell, MD, and Justin Muste, MD, sit down with Wills Eye fellow Flavius Beca, MD, to discuss the highs and lows of fellowship training, including successful cases of uveitis, clinical pearls for pneumatic retinopexy, and the challenges of treating retinal tears and detachments with vitrectomy and scleral buckling.
New Retina Radio Journal Club w/ VBS: Assessing Surgical Competency Among Retina Fellows: Perspectives from Directors and Graduates
How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new survey study comparing perspectives from fellowship program directors and recent graduates on surgical volumes, teaching tools, autonomy, and competency benchmarks. The group explores areas of agreement, gaps in curren
DME, DR, and Next-Generation Therapies
How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dosing strategies that balance durability, efficacy,
Wet AMD and Next-Generation Therapies
How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching from legacy agents to next-generations treatments.
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)
Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustain
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)
Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy.
Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)
In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice.
D
Global Discussions in GA: Educating Patients and Encouraging Follow-Up
How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients and caregivers. Plus, are AREDS supplements an opti
Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring
At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and FAF imaging, discusses patient/caregiver educatio
Endophthalmitis Rates With and Without Antibiotic Prophylaxis
Does antibiotic prophylaxis prior to intravitreal injection affect the risk of endophthalmitis? Join New Retina Radio Journal Club with VBS moderator Alexis Warren, MD, as she and panelists Sruthi Arepalli, MD, and Jesse Sengillo, MD, sort out the details of a recent paper and discuss whether these findings alter clinical practice.
The Nuts and Bolts of GA Therapy: Wrapping Up the Conversation
How do you decide when GA patients are ready for complement inhibition—and how do you keep them on therapy in the real world? In episode 3 of The Nuts and Bolts of GA Therapy, moderator Charles Wykoff, MD, PhD, speaks with Kenneth Fan, MD, MBA, and Sruthi Arepalli, MD, about early vs conservative initiation, nuanced counseling on expectations and safety, and how imaging informs treatment decisions
AAO '25: GLP-1s and AMD, and Parity in Retina Care
What do GLP-1 receptor agonists mean for the future of retinal disease? Aleksandra Rachitskaya, MD, joins us to review the ever-evolving data on the relationship between retinal disease and GLP-1 RA use. Could these drugs protect against the development of retinal disease? And Julia Haller, MD, explains her vision of what the future of retina looks like. Who needs to be included in the crafting of
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE
Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME. And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease
The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offered a survey of developmental projects in dry AMD. What should we look forward to? And Michel Michaelides, MD, shares details from the DRAGON study, which examined the safety and efficacy of tinlarebant (Belite Bio) for the treatment of Stargardt disease. Could
The Nuts and Bolts of GA Therapy: The Discussions Continue
How do you create clear, durable treatment plans for real-world GA patients? In episode 2 of The Nuts and Bolts of GA Therapy, host Charles Wykoff, MD, PhD, joins Hasenin Al-khersan, MD, and Nakul Singh, MD, to dissect real-world cases and discuss choosing monthly or EOM week dosing regimens, engaging caregivers, and reconciling clinical trial data with real-world experiences.
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR
Could optogenetics represent the innovative thinking needed to restore some function in retinitis pigmentosa (RP) patients? Allen Ho, MD, joins us to discuss the state of play in optogenetics, specifically regarding MCO-010 (Nanoscope Therapeutics). What have we seen in the several years since the first patients with RP were dosed with MCO-010 in the RESTORE study? And Charles Wykoff, MD, PhD, joi
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care
How do costs and reimbursements shape practice patterns regarding panretinal photocoagulation (PRP)? Niki Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new time-driven activity-based costing study by Berkowitz et al. The panel explores how procedure time, margins, and CMS reimbursement affect the role of PRP versus anti-VEGF therapy, and reflects on
The Nuts and Bolts of GA Therapy: The Opening Sessions
How do retina specialists first broach the topic of complement inhibition for GA therapy? In episode 1 of this miniseries, moderator Charles Wykoff, MD, PhD, speaks with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD, about timing treatment conversations, managing patients with one good and one bad eye, and addressing whether patients can maintain driving. Editorially independent content, su
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision
How should retina specialists reframe their approach to GA therapy? In the final episode of this New Retina Radio miniseries, moderator John Kitchens, MD joins experts Margaret Chang, MD, MS; David Eichenbaum, MD; and Ferhina Ali, MD, MPH, to explore how to shift doctor mindsets from restoring vision to preserving it. The panel discusses challenges of counseling without clear imaging endpoints, th
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation
Should GA therapy start monthly—or is less-than-monthly treatment enough? In episode 3 of this New Retina Radio miniseries, moderator John Kitchens, MD joins David Eichenbaum, MD; Margaret Chang, MD, MS; and Ferhina Ali, MD, MPH, to share best practices in real-world GA care. The panel debates dosing strategy in light of long-term data, compares safety/efficacy considerations for pegcetacoplan vs
Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations
How do you educate and empower patients to make informed decisions about geographic atrophy (GA) therapy? In episode 2 of this New Retina Radio miniseries, moderator John Kitchens, MD guides Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD, through practical strategies for patient education. The panel covers plain-language analogies for GA, using OCT and fundus photos, coordi
Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention
What does it mean to truly keep patients at the center of geographic atrophy (GA) therapy? In this first episode of a four-part New Retina Radio miniseries, moderator John Kitchens, MD, leads a discussion with experts Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD. The panel explores the social impact of GA and highlight the importance of early intervention, imaging, and pa
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab
What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentech/Roche) and are switched to high-dose aflibercept (Eylea HD, Regeneron)? Ben Young, MD, moderates a discussion with Pheobe Mellen, MD, and Jordan Deaner, MD, exploring real-world outcomes from a retrospective study of 135 eyes. The group dives into the implic
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed? And Ehsan Rahimy, MD, reviews findings from a
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders
Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes after 5 years of PDS treatment. And Krishna Mukkamala,
New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy
What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to discuss a new retrospective cohort study by Rahimy et al. The panel explores how obstructive sleep apnea impacts the progression of diabetic retinopathy and elevates the risk for systemic vascular events suc
The State of Geographic Atrophy Around the Globe: Part 2 of 2
Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatmen
The State of Geographic Atrophy Around the Globe: Part 1 of 2
The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina specialists—Daniel Ting, MD, PhD; Paulo Eduardo Stanga,
Diabetic Retinopathy Severity and Income Status
Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe Mellen, MD, and Jordan Deaner, MD, about a new retrospective cohort study from the Duke Eye Center than examines differences in DR severity at presentation between patients from the lowest- and highest-income ZIP codes, explores how income-based
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy
What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.
GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates
How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion.
Photobiomodulation for Age-related Macular Degeneration
What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study’s data.
Duke AVS Clips: PVR, DR, Imaging, and MTM
Duke faculty interview key lecturers from the 2025 Duke AVS Course about their podium talks. Jason Hsu, MD, discusses the best ways to manage proliferative vitreoretinopathy, Majda Hadziahmetovic, MD, shares new data on the effect of GLP-1 receptor agonists on diabetic retinopathy, Aleksandra V. Rachitskaya, MD, explains the value of multimodal Imaging in adults with a history of prematurity, and
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI
Faculty from the 2025 Duke AVS Course ask key lecturers to share pearls from their presentations. Lejla Vajzovic, MD, discusses various pediatric retinal conditions that can manifest later in life, Jason Fan, MD, explains trends in anesthesia use for open-globe surgery, and Glenn J. Jaffe, MD, examines the role of AI in retina clinical trials.
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs
During the 2025 Duke AVS Course, Duke faculty sat down with several key lecturers to discuss their presentations. Avni P. Finn, MD, MBA, discussed her experiences delivering subretinal gene therapy, David Zacks, MD, PhD, explored important factors in retinal detachment repair, Xi Chen, MD, PhD, highlighted the various surgical approaches for young patients who present without a posterior vitreous
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data
Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodula
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline
Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were
GLP-1s and Risk of Age-Related Ocular Disease
How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to examine a retrospective study published in Ophthalmology using TriNetX data to compare 5-year ocular outcomes across medication cohorts. Do these data suggest a protective benefit for GLP-1s—and does it matter for c
Fellow Eye RRD Risk per IRIS Registry
Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repaired? What concomitant conditions do fellow eyes with RRD have? What risk factors exist for fellow eye RRD? And which procedures are used to repair fellow eye RRD? Moderator Barton Blackorby, MD, and panelists Louis Cai, MD, and Hong-Uyen Hua, MD, dissect the l
Rates of Ocular AEs After Faricimab Injection
What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data show? And do these data effect the clinical pattern
Treating Geographic Atrophy (GA) In Your Practice
Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.
Using OCT Angiography to Distinguish RVO and RAO
How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which specific OCT angiography findings may indicate ref
OCT Angiography in a Real-world CSR Case
What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography.
This episode is supp
Switching from Aflibercept to Faricimab in Wet AMD Patients
Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?
What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins.
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's
How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database review of real-world patients with proliferative DR revealed how few patients are concordant with the strict dosing schedule of Protocol S, and shares which baseline factors were linked to lack of concordance. And Dilraj Grewal, MD, provides an
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?
Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari, MD, review a decade-long case control-control study assessing risk of AMD in non-diabetic patients who have been taking metformin for any reason. They ask whether the study's blindspots undercut its findings, and speculate what other questi
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA stu
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD
The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the pr
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement
Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal manifestations. Was there a clear—or even an opaque—connection between the two? And Paul Hahn, MD, PhD, sits
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?
We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a co
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis Prevention
In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study comparing endophthalmitis rates following anti-VEGF injections with pre-treatment using either 5% Povidone Iodine or 0.05% Chlorhexidine. They highlight how prefilled syringes can reduce the risk of endophthalmitis and explore the implications fo
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR
Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about ano
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO
What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic with an RAO, review academic centers' model for rapid
ASRS ’24: C1q Inhibition and Metformin for AMD
Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest resea
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical
ASRS ’24: PAVILION at 100 Weeks
The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what it w
Recommended
Dispatches from Reality
The Conspiracy Files
TechnoSnobCast
The Young and Called Podcast .
Snoop Dogg - Flash Biográfico
Deadline: White House
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
The Daily Conspiracy Podcast
2819 Church
Markus Schulz presents Global DJ Broadcast
Bad Friends
The Bill Simmons Podcast
